Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 1, 2006, Pages 310-317

  Jumbe, Nelson L ^a,b   Louie, Arnold ^a   Miller, Michael H ^b   Liu, Weiguo ^a,b   Deziel, Mark R ^a   Tam, Vincent H ^a   Bachhawat, Reetu ^b   Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GENE PRODUCT; LEVOFLOXACIN; PROTEIN PARC; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; QUINOLONE EFFLUX PUMP; RESERPINE RESPONSIVE PUMP; SPARFLOXACIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG INDICATION; GENE OVEREXPRESSION; HEALTH CARE POLICY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PUBLIC HEALTH; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; THIGH;

ANIMALS; ANTI-INFECTIVE AGENTS; CARRIER PROTEINS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, ANIMAL; MODELS, BIOLOGICAL; PNEUMOCOCCAL INFECTIONS; QUINOLONES; STREPTOCOCCUS PNEUMONIAE;

EID: 29944438551     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.1.310-317.2006     Document Type: Article

References (29)

1. Andes, D., and W. A. Craig. 2002. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46:1665-1670.
2. Balas, D., E. Férnandez-Moreira, and A. G. de la Campa. 1998. Molecular characterization of the gene encoding the DNA gyrase A subunit of Streptococcus pneumoniae. J. Bacteriol. 180:2854-2861.
3. Bartlett, J. G., R. F. Breiman, L. A., Mandell, and T. M. File, Jr. 1998. Community-acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. 26:811-838.
4. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
5. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239.
6. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibiotic dosing of mice and men. Clin. Infect. Dis. 26:1-10.
7. Craig, W. A. 2001. Does the dose matter? Clin. Infect. Dis. 33:S233-S237.
8. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. University of Southern California, Los Angeles.
9. Eagle, H., R. Fleischman, and M. Levy. 1953. Continuous versus discontinuous therapy with penicillin: the effect of interval between injections on therapeutic efficacy. N. Engl. J. Med. 248:481-488.
10. Garcia-Rey C., L. Aguilar, F. Baquero, J. Casal, and R. Dal-Re. 2002. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J. Clin. Microbiol. 40:159-164.
11. Gill, M. J., N. P. Brenwald, and R. Wise. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:187-189.
12. Goldstein, E. J., and S. M. Garabedian-Ruffalo. 2002. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin. Infect. Dis. 35:1505-1511.
13. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bacchawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Investig. 112:275-285.
14. Lacy, M. K., W. Lu, X. Xu, P. R. Tessier, D. P. Nicolau, R. Quintiliani, and C. H. Nightingale. 1999. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. 43:672-677.
15. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1990. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand. J. Infect. Dis. 74:179-184.
16. Muñoz, R., M. Bustamante, and A. G. de la Campa. 1995. Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance. J. Bacteriol. 177:4166-4170.
17. Muñoz, R., and A. G. de la Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
18. NCCLS. 1997. NCCLS publication M7-A4. NCCLS, Wayne, PA.
19. Niederman, M. S., L. A. Mandell, A. Anzueto, J. B. Bass, W. A. Broughton, C. D. Campbell, N. Dean, T. File, M. J. Fine, P. A. Gross, F. Martinez, T. J. Marrie, J. F. Plouffe, J. Ramirez, G. A. Sarosi, A. Torres, R. Wilson, and V. L. Yu. 2001. Guidelines for the management of adults with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 163:1730-1754.
20. Pan, X.-S., and L. M. Fisher. 1996. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178:4060-4069.
21. Pan, X.-S., J. Ambler, S. Mehtar, and M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
22. Puthisigamani, M., G. L. Drusano, W. Liu, V. H. Tam, M. R. Deziel, and A. Louie. Gemifloxacin pharmacokinetic and pharmacodynamic studies using isogenic Streptococcus pneumoniae wild-type +/- efflux pumps +/- a parC mutation in a murine thigh infection model, abstr. 471. Prog. Abstr. Infect. Dis. Soc. Am. 39th Annu. Meet. Infectious Disease Society of America, San Francisco, Calif.
23. Sahm, D. F., J. A. Karlowsky, L. J. Kelly, I. A. Critchley, M. E. Jones, C. Thornsberry, Y. Mauriz, and J. Kahn. 2001. Need for annual surveillance of antimicrobial resistance in Streptococcus peumoniae in the United States: 2 year longitudinal analysis. Antimicrob. Agents Chemother. 45:1037-1042.
24. Scaglione, F., J. W. Mouton, R. Mattina, and F. Fraschini. 2003. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob. Agents Chemother. 47:2749-2755.
25. Schmitz, F.-J., A. C. Fluit, M. Luckefahr, B. Engler, B. Hoffmann, J. Verhoef, H.-P. Heinz, U. Hadding, and M. E. Jones. 1998. The effect of reserpine, an inhibitor of multidrug efflux pumps on the in vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 42:807-810.
26. Schumitzky, A., R. Jelliffe, and M. van Guilder. 1994. NPEM: a program for pharmacokinetic population analysis. Clin. Pharmacol. Ther. 55:163.
27. Wong, F. A., S. J. Juzwin, and S. C. Flor. 1997. Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine. J. Pharm. Biomed. Anal. 15:765-771.
28. Wright, D. H., V. K. Herman, F. N. Konstantinides, and J. C. Rotschafer. 1998. Determination of quinolone antibiotics in growth media by reversed-phase high-performance liquid chromatography. J. Chromatogr. B 709:97-104.
29. Yamaoko, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.